Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous TP53 R175H mutant-specific HLA-A*02:01-restricted TCR gene engineered T lymphocytes NT-175

A preparation of autologous T lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted TP53 (p53) R175H mutant, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous TP53 R175H mutant-specific HLA-A*02:01-restricted TCR gene engineered T lymphocytes NT-175 target and bind to tumor cells expressing the TP53 R175H mutant. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the TP53 R175H mutant. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
Synonym:autologous P53-specific TCR-T cells NT-175
autologous TP53 R175H mutant-specific HLA-A*02:01-restricted TCR T cells NT-175
Code name:NT 175
NT-175
NT175
Search NCI's Drug Dictionary